Wang B - Search Results

1

Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.

Jin J, Cao J, Li B, Li T, Zhang J, Cao J, Zhao M, Wang L, Wang B, Tao Z, Hu X. Jin J, et al. Among authors: wang l, wang b. Cancer. 2023 Mar 15;129(6):845-859. doi: 10.1002/cncr.34618. Epub 2023 Jan 18. Cancer. 2023. PMID: 36655350 Free article.

2

Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.

Wang J, Li J, Hong X, Tang W, Hu X, Wang B, Guo Y. Wang J, et al. Among authors: wang b. Oral Oncol. 2008 May;44(5):464-70. doi: 10.1016/j.oraloncology.2007.06.004. Epub 2007 Sep 7. Oral Oncol. 2008. PMID: 17826303

3

MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls.

Zhang J, Qiu LX, Wang ZH, Wu XH, Liu XJ, Wang BY, Hu XC. Zhang J, et al. Breast Cancer Res Treat. 2010 Sep;123(2):549-55. doi: 10.1007/s10549-010-0783-5. Epub 2010 Feb 9. Breast Cancer Res Treat. 2010. PMID: 20143151

4

Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis.

Zhang J, Qiu LX, Wang ZH, Leaw SJ, Wang BY, Wang JL, Cao ZG, Gao JL, Hu XC. Zhang J, et al. Breast Cancer Res Treat. 2010 Nov;124(2):419-24. doi: 10.1007/s10549-010-0846-7. Epub 2010 Mar 19. Breast Cancer Res Treat. 2010. PMID: 20300826

5

Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility.

Qiu LX, Zhang J, Li WH, Zhang QL, Yu H, Wang BY, Wang LP, Wang JL, Wang HJ, Liu XJ, Luo ZG, Wu XH. Qiu LX, et al. Mol Biol Rep. 2011 Apr;38(4):2295-9. doi: 10.1007/s11033-010-0361-2. Epub 2010 Nov 5. Mol Biol Rep. 2011. PMID: 21052845

6

Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.

Sun S, Wang LP, Zhang J, Yang XY, Zhang QL, Jia Z, Hu XC, Wang BY. Sun S, et al. Med Oncol. 2012 Jun;29(2):418-24. doi: 10.1007/s12032-011-9839-6. Epub 2011 Feb 6. Med Oncol. 2012. PMID: 21298496 Clinical Trial.

7

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. Wang L, et al. Among authors: wang z, wang b. BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248. BMC Cancer. 2011. PMID: 21676217 Free PMC article. Clinical Trial.

8

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X. Zhao X, et al. Among authors: wang z, wang b. BMC Cancer. 2011 Sep 22;11:403. doi: 10.1186/1471-2407-11-403. BMC Cancer. 2011. PMID: 21936956 Free PMC article. Clinical Trial.

9

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC. Zhang J, et al. Cancer Chemother Pharmacol. 2013 Jan;71(1):103-13. doi: 10.1007/s00280-012-1983-y. Epub 2012 Oct 2. Cancer Chemother Pharmacol. 2013. PMID: 23053266 Clinical Trial.

10

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.

Zhang J, Jia Z, Ragaz J, Zhang YJ, Zhou M, Zhang YP, Li G, Wang BY, Wang ZH, Hu XC. Zhang J, et al. BMC Cancer. 2013 Jan 31;13:42. doi: 10.1186/1471-2407-13-42. BMC Cancer. 2013. PMID: 23368410 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47,373 results

Search Page

Filters